Lipid and protein oxidation products, antioxidant status and vascular complications in poorly controlled type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 12, Issue 1, 2012, Pages 33-39

  Bigagli, E ^a   Raimondi, L ^a   Mannucci, E ^b   Colombi, C ^b   Bardini, G ^a   Rotella, C M ^a   Lodovici, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Careggi Teaching Hospital   (Italy)

Author keywords

antioxidant status; C reactive protein; endothelial dysfunction; lipoperoxidation; poorly controlled type 2 diabetes; protein oxidation.

Indexed keywords

ANTIOXIDANT; C REACTIVE PROTEIN; FERRIC REDUCING ABILITY OF PLASMA; HEMOGLOBIN A1C; IRON DERIVATIVE; LIPID; MALONALDEHYDE; PROTEIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE COURSE; ENZYME ACTIVITY; GLYCEMIC CONTROL; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; VASCULAR DISEASE;

EID: 84858235604     PISSN: 14746514     EISSN: 17534305     Source Type: Journal    
DOI: 10.1177/1474651411435588     Document Type: Article

References (32)

1. Kruger DF. Exploring the pharmacotherapeutic options for treating type 2 diabetes. Diabetes Educ. 2008 ; 34 (suppl 3). 60S - 65S
2. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-72 (Pubitemid 351831357)
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-53
4. Mannucci E, Monami M, Lamanna C, et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009 ; 19: 604-12
5. Çimen K. Diabetic cardiovascular complications appear to be multifactorial in origin, but in particular, glycoxidative stress (GOS) has been suggested to be the unifying link between the various molecular disorders in DM. Cardiovasc Med J. 2010 ; 4: 240-56
6. Guillausseau PJ, Meas T, Virally M, et al. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab. 2008 ; 34: S43-48
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001 ; 414: 813-20 (Pubitemid 34000785)
8. Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med. 2006 ; 41: 177-84 (Pubitemid 43928495)
9. Rosen P, Nawroth PP, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001 ; 17: 189-212 (Pubitemid 32624602)
10. Pu LJ, Lu L, Xu XW, et al. Value of serum glycated albumin and high-sensitivity C reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2006 ; 5: 27
11. Zhou T, Zhou KK, Lee K, et al. The role of lipid peroxidation products and oxidative stress in activation of the canonical wingless-type MMTV integration site (WNT) pathway in a rat model of diabetic retinopathy. Diabetologia. 2011 ; 54: 459-68
12. Drummond GR, Selemidis S, Griendling KK, et al. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011 ; 10: 453-71
13. Lapolla A, Piarulli F, Sartore G, et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care. 2007 ; 30: 670-76 (Pubitemid 46354351)
14. Likidlilid A, Patchanans N, Peerapatdit T, et al. Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients. J Med Assoc Thai. 2010 ; 93: 682-93
15. Al-Rawi NH. Oxidative stress, antioxidant status and lipid profile in the saliva of type 2diabetics. Diab Vasc Dis Res. 2011 ; 8: 22-8
16. Lodovici M, Giovannelli L, Pitozzi V, et al. Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control. Mutat Res. 2008 ; 638: 98-102
17. Lodovici M, Bigagli E, Bardini G, et al. Lipoperoxidation and antioxidant capacity in patients with poorly controlled type 2 diabetes. Toxicol Ind Health. 2009 ; 25: 337-41
18. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004 ; 109: IV6-19
19. Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 ; 107: 499-511 (Pubitemid 36158056)
20. Hernandez-Mijares A, Rocha M, Apostolova N, et al. Mitochondrial complex I impairment in leukocytes from type 2 diabetic patients. Free Radic Biol Med. 2011 ; 50: 1215-21
21. Zoppini G, Targher G, Negri C, et al. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care. 2009 ; 32: 1716-20
22. Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in non-proteinuric patients with type 1 diabetes. Clin J Am Nephrol. 2008 ; 3: 706-13
23. Beauchamp C, Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal Biochem. 1971 ; 44: 276-87
24. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of 'antioxidant power': the FRAP assay. Anal Biochem. 1996 ; 239: 70-76
25. Mateos R, Lecumberri E, Ramos S, et al. Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 ; 827: 76-82 (Pubitemid 41551599)
26. Correa-Salde V, Albesa I. Reactive oxidant species and oxidation of protein and haemoglobin as biomarkers of susceptibility to stress caused by chloramphenicol. Biomed Pharmacother. 2009 ; 63: 100-04
27. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996 ; 19: 257-67 (Pubitemid 26070354)
28. Piarulli F, Sartore G, Ceriello A, et al. Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia. 2009 ; 52: 1419-25
29. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond). 2004 ; 1 (1). 10
30. Singhania N, Puri D, Madhu SV, et al. Assessment of oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy. QJM. 2008 ; 101: 449-55 (Pubitemid 351791528)
31. Targher G, Bertolini L, Zoppini G, et al. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med. 2005 ; 22: 999-1004 (Pubitemid 41025995)
32. Turk HM, Sevinc A, Camci C, et al. Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus. Acta Diabetol. 2002 ; 39: 117-22